Lucier to Lead New ABI, DiVincenzo Takes Over at Millipore's Bioscience Division, Hood Joins Geospiza Board, and More | GenomeWeb
NEW YORK (GenomeWeb News) – Greg Lucier, chairman and CEO of Invitrogen, will assume that some role following consummation of the firm’s merger with Applied Biosystems. Mark Stevenson, currently president and COO of ABI, will retain that role in the merged company, which will keep the ABI name. Tony White, chairman, president, and CEO of ABI parent Applera, will serve as a consultant to ABI following the deal.
 

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.